Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to arabinogalactans which are useful as therapeutic, prophylactic or diagnostic agents in connection with the presence of microorganisms.
• the invention also includes processes for.manufacturing the arabinogalactans and a composition containing same.
• the present invention thus relates to compositions and arabinogalactans useful for therapeutic treatment of infections caused by patogenic microorganisms, such as bacteria, particularly intestinal bacteria, such as Gram-negative types.
• the invention is particularly applicable to bacterias of the genus Enterobacteriaceae, such as Escherichia coli bacteria, particularly K88+7
• the compositions of the invention are useful also for prophylactic and diagnostic procedures.
• the invention also includes a process for therapeutic treatment of mammals including man. Although the invention is not limited in such a way it will in the following be illustrated essentially in connection with the bacterium E.coli.
• Bacterial infection courses are often initiated by the fact that the bacterium has the ability to adhere to epithelial tissue. This adhereing capacity is specific in that different bacteria adhere preferentially to different types of tissues.
• E.coli possessing fimbriae designated K-antigene K88 adheres well to intestinal epithelium of piglets (ref. 1). It has also been shown that the K88 fimbriae are responsible to the ability of E.coli K88+ to agglutinate guinea-pig erythrocytes (ref. 2).
• the mutant lacking K88-fimbriae lacks ability to adhere to intestinal epithelium with the result that said E.coli bacteria cannot colonize the intestinals of pigs (ref. 3). It has, moreover, been shown that the K88-fimbriae recognize some structure on the "brush border" membranes of the intestinal epithelium. Thus, it has been shown that certain pigs lack this structure in the intestinal epithelium and that this fact results in said pigs being resistant to intestinal infections caused by E.coli K88+.
• the present invention accordingly provides for arabinogalactans from trees of the genus Cocos or compositions containing such arabinogalactans having the ability of replacing the normal receptor in vivo in relation to patogenic microorganisms capable of providing infections in man and animals.
• Another object of the invention is to provide such composition or substance which in addition to the therapeutic use thereof also can be used diagnostically.
• microorganism used in the present disclosure is intended to include bacteria, viruses, animal cells and plant cells.
• the invention is particularly directed to the receptor structure for K88-fimbriated E.coli but is not limited to this type of bacteria.
• the arabinogalactans involved in the present invention may thus be used therapeutically, prophylactically or diagnostically.
• the arabinogalactans according to the invention are preferably recovered from trees of the species Cocos nucifera, i.e. trees of the palmtype. It is-mainly the cocoa-nuts of the trees which contain the compounds of interest, i.e. the milk of the cocoa-nut or its meat, for example as available in dried form under the name copra.
• the invention is particularly applicable to diarrhoea-generating microorganisms, for example E.coli K88+ or closely related bacteria.
• the invention also provides for a process for recovering such arabinogalactans or solvolysates thereof from cocoa-nut meat, dried such meat, i.e. copra, or defatted cocoa-nut meat.
• Such recovery is suitably performed by extraction while using a hydrofilic extraction means, preferable a water-based extraction agent.
• a hydrofilic base from which the desirable arabinogalactans can be recovered in a suitable manner, for example by freezedrying, evaporation or the like.
• the active arabinogalactans according to the present invention may in a conventional manner be formulated for use in human or veterinary medicine for therapeutic, prophylactic os diagnostic purposes.
• the composition or the pharmaceutical preparation may contain the active arabinogalactans in combination with a pharmaceutically acceptable carrier which may be solid, semi-solid or liquid depending on the manner of administration and further factual circumstances.
• the active substances may also be used as such without addition of carrier materials.
• the compositions are prepared in full comformity with conventional pharmaceutical practice.
• compositions of this invention include tablets, capsules, syrups, suspensions, solutions, concentrates, reconstitutable powders in sterile forms suitable for injection or infusion.
• Such compositions may contain conventional pharmaceutically acceptable materials, such as diluents, binders, colouring agents, flavouring agents, preservatives, desintegrants and the like in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibiotics.
• the present compositions are used for therapeutic or prophylactic purposes to treat or prevent diarrhoea in pigs, particularly piglets.
• the active arabinogalactans are suitably dissolved in the drinking water of the animal, and in particularly severe cases it can be administered by oral gavage.
• the active substance may be added directly to the animal's diet, either per se or as a concentrate in aqueous solution or other suitable formulation, for example together with a diluent to facilitate dosage.
• Suitable quantities can be determined on a case to case basis and may be of the order of grams per day, for example 0.1-50 grams per day.
• bacteria of the type E.coli 0 149 K88+ were used.
• the bacteria were cultivated on CFA-medium at +37°C for 18 hours.
• the bacterial growth wass slurried in PBS, pH 7.2 to a density of 1 ⁇ 10 10 bacteria/ml.
• K88-fimbriae were obtained in the following manner.
• the bacterial strain was cultivated on Roux flasks with CFA-agar. After incubation at +37° for 24 hours the bacteria were harvested by adding 10 ml PBS/flask and sterile glass balls. The flasks were shaken and the bacterial suspension removed. The bacteria were pelletized by centrifugation (3000 x g, +4°, 30 min.). The supernatant was removed by suction. The bacteria were resuspended in 10 ml PBS and the suspension was treated in a Waring blendor 2 x 20 seconds. The suspension was centrifuged (5000 x g, +4°, 30 min.) to pelletize the bacteria. The supernatant containing fimbriae was removed by suction.
• the bacterial pellet is resuspended, treated in a Waring blendor and after centrifugation the supernatant is again recovered.
• the two supernatants are pooled and ammonium sulphate is added to a concentration of 30%. After stirring the supernatants are allowed to stand at +4°C for 18 hours, centrifugation then taking place at 5000 x g. The supernatant was separated and the precipitation was dialyzed against PBS. The solubilized fimbriae fraction was precipitated with ammonium sulphate once more and dialyzed.
• Haemagglutination is performed using erythrocytes from guinea-pigs (GRBC) suspended to a concentration of 3% v/w in PBS.
• the agglutination tests were carried out so that 50 / ul GRBC were mixed with 2-step dilution of antigen 50 / ul bacterial suspension or 50 / ul fimbriae suspension and 50 / ul PBS in microtitre plates.
• the plates were sealed with Para- film and incubated at +44°C for 4 hours and were then recorded.
• the last well wherein agglutination could be read by the eye is considered as 1 haemagglutinating unit ( 1 HU).
• Cocoa-nut milk (22 litres) were concentrated to 2 liters by evaporation, and after centrifugation flocculated fat was removed by filtration. The solution was dialyzed and the high molecular fraction, molecular weight > about 5000, (30g) were passed through a column packed with Sephadex G15. The "Void"-fraction from the column was collected (25g). Analysis of the fraction showed that it contained a polysaccharide containing arabinose and galactose units.
• the fraction obtained was hydrofilized and the residue was dissolved in water to form an aqueous solution subjected to 2-step serial dilution for later use in inhibition of haemagglutination.
• the results of the inhibition experiments are given in Table 1 below.
• Example 2 is repeated while using so called copra which is constituted by dried meat from cocoa-nut. After separation of fat in connection with the process there is obtained an aqueous solution which is subjected to 2-step serial dilution. The results of the inhibition experiments are given in Table 1 below.
• the animals used were 6 piglets released by sectio caesarea on day 1. These piglets had accordingly up to the clinical testing never been confronted with any environmental hazards including foreign microorganisms.
• the piglets were divided up into 2 groups, one group being designated I and the other group being designated II.
• the first group I was challenged with Coli 0149 (LT + ST + K88 + ) in combination with an aqueous solution of the cocoa-nut milk arabinogalactan prepared in accordance with Example 1 above.
• the other group II was challenged with the same E.coli only.
• the two piglets of Group I sacrified 06.00, day 3 showed healthy intestinals, and one of the piglets suffered some liquid release in jejunum, ileum and colon,
• the two piglets from Group II showed strong interior haemorrhage and liquid release in jejunum and ileum.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Materials Engineering (AREA)
• Polymers & Plastics (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=20352412

Family Applications (1)

Country Status (4)

Cited By (4)

Family Cites Families (1)

• 1983
  • 1983-09-08 SE SE8304821A patent/SE8304821L/xx not_active Application Discontinuation
• 1984
  • 1984-08-20 EP EP84850245A patent/EP0138784A3/de not_active Withdrawn
  • 1984-08-31 DK DK419284A patent/DK419284A/da not_active Application Discontinuation
  • 1984-09-07 JP JP59186623A patent/JPS6084302A/ja active Pending

Also Published As

Similar Documents

Legal Events